Views Expressed Disclaimer:
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Highlights

  • BWXT reported Q4 EPS of USD 1.08, surpassing expectations.
  • Commercial revenue surged 95% in Q4, lifting backlog levels.
  • FY2026 guidance increased, though margin timing risks remain.

BWX Technologies, Inc. (NYSE:BWXT) reported quarterly earnings of USD 1.08 per share. Revenue for the quarter reached USD 885.84 million.

The company recorded a return on equity of 30.70% and a net margin of 10.04% during the period. Despite the earnings outperformance, the stock declined 3.90% to close at USD 198.38 on February 23. Over the past year, shares have gained 98.58%, though they are down 4.51% over the last month.

Record 2025 Performance
BWXT closed fiscal 2025 with revenue rising 18% year over year. Adjusted EBITDA increased 15%, while earnings per share climbed 20%. Free cash flow advanced 16%, and year-end backlog stood at USD 7.3 billion, reflecting 15% annual growth.

Commercial operations contributed significantly to the quarter. Q4 commercial revenue rose 95%, including 31% organic growth. Commercial backlog reached USD 1.7 billion, marking an 85% increase from the prior year. BWXT Medical crossed USD 100 million in annual revenue, with continued double-digit growth expected.

M&A Activity and Project Awards
Recent acquisitions, including AOT and Kinectrics, supported new contract wins and expanded technical capabilities. During the period, the company secured a USD 1.6 billion high-purity depleted uranium contract and took on an owner’s engineer role for the AP1000 project in Bulgaria.

BWXT also invested in facilities such as its Innovation Campus, a Centrifuge facility, and a Digital Center to expand advanced nuclear and special materials capacity.

2026 Guidance and Margin Outlook
For fiscal 2026, BWXT projected revenue of approximately USD 3.75 billion. Adjusted EBITDA is expected between USD 645 million and USD 660 million, while earnings per share are guided to a range of USD 4.55 to USD 4.70. Free cash flow is estimated between USD 305 million and USD 320 million.

The company indicated that certain government programs begin at lower initial margins. Approximately 55% of EBITDA is expected to be weighted toward the second half of the year, with first-quarter EBITDA likely flat, pointing to potential short-term margin pressure.

Broker Consensus Indicates Moderate Upside with Buy Rating
According to EODHD/Others data as of 24 Feb 2026, Analysts maintain a positive outlook on BWX Technologies Inc, with the current consensus recommendation at 2.08 (BUY). The average target price stands at USD 224.44, implying a potential upside of approximately 13.14% from current levels.

The company’s long-term growth (LTG) estimate of 14.59% reflects solid earnings expansion prospects, supported by steady demand in the aerospace and defense sector. Overall, broker sentiment signals confidence in future growth with meaningful near-term upside potential.

Business Overview
BWX Technologies supplies nuclear components and services to the U.S. government and commercial markets. Its operations include naval nuclear propulsion systems, small modular reactor development, nuclear fuel technologies, and medical radioisotopes used in diagnostic imaging and cancer treatment.

With quarterly earnings above expectations and fiscal 2026 guidance increased, BWX Technologies enters the new year with higher backlog and expanding commercial activity. However, margin timing and program mix may influence near-term quarterly performance as the company progresses through 2026.

FAQs

Q1. How did BWX Technologies perform in Q4?
The company reported Q4 EPS of USD 1.08 and revenue of USD 885.84 million.

Q2. What is BWXT’s guidance for FY2026?
BWXT expects revenue of about USD 3.75 billion and EPS between USD 4.55 and USD 4.70.

Q3. Why did the stock decline after results?
Shares moved lower amid expectations of back-half weighted EBITDA and near-term margin pressure.